89 related articles for article (PubMed ID: 33199028)
1. The optimal HPV-screening protocol in Eastern-Europe: The example of Slovenia.
Jansen EEL; Ivanuš U; Jerman T; de Koning HJ; de Kok IMCM
Gynecol Oncol; 2021 Jan; 160(1):118-127. PubMed ID: 33199028
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia.
Berkhof J; Bogaards JA; Demirel E; Diaz M; Sharma M; Kim JJ
Vaccine; 2013 Dec; 31 Suppl 7():H71-9. PubMed ID: 24332299
[TBL] [Abstract][Full Text] [Related]
3. Cervical cancer screening program based on primary DNA-HPV testing in a Brazilian city: a cost-effectiveness study protocol.
Teixeira JC; Vale DB; Bragança JF; Campos CS; Discacciati MG; Zeferino LC
BMC Public Health; 2020 Apr; 20(1):576. PubMed ID: 32345284
[TBL] [Abstract][Full Text] [Related]
4. Primary screening for human papillomavirus compared with cytology screening for cervical cancer in European settings: cost effectiveness analysis based on a Dutch microsimulation model.
de Kok IM; van Rosmalen J; Dillner J; Arbyn M; Sasieni P; Iftner T; van Ballegooijen M
BMJ; 2012 Mar; 344():e670. PubMed ID: 22391612
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of cervical cancer screening with primary human papillomavirus testing in Norway.
Burger EA; Ortendahl JD; Sy S; Kristiansen IS; Kim JJ
Br J Cancer; 2012 Apr; 106(9):1571-8. PubMed ID: 22441643
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of HPV-based cervical screening based on first year results in the Netherlands: a modelling study.
Jansen E; Naber SK; Aitken CA; de Koning HJ; van Ballegooijen M; de Kok I
BJOG; 2021 Feb; 128(3):573-582. PubMed ID: 32638462
[TBL] [Abstract][Full Text] [Related]
7. Optimal Cervical Cancer Screening in Women Vaccinated Against Human Papillomavirus.
Kim JJ; Burger EA; Sy S; Campos NG
J Natl Cancer Inst; 2017 Feb; 109(2):. PubMed ID: 27754955
[TBL] [Abstract][Full Text] [Related]
8. Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the National Cervical Screening Program.
Lew JB; Simms KT; Smith MA; Hall M; Kang YJ; Xu XM; Caruana M; Velentzis LS; Bessell T; Saville M; Hammond I; Canfell K
Lancet Public Health; 2017 Feb; 2(2):e96-e107. PubMed ID: 29253402
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness of Primary HPV Screening Strategies and Triage With Cytology or Dual Stain for Cervical Cancer.
Tantitamit T; Khemapech N; Havanond P; Termrungruanglert W
Cancer Control; 2020; 27(1):1073274820922540. PubMed ID: 32372659
[TBL] [Abstract][Full Text] [Related]
10. Adapting cervical cancer screening for women vaccinated against human papillomavirus infections: The value of stratifying guidelines.
Pedersen K; Burger EA; Nygård M; Kristiansen IS; Kim JJ
Eur J Cancer; 2018 Mar; 91():68-75. PubMed ID: 29335156
[TBL] [Abstract][Full Text] [Related]
11. Age at last screening and remaining lifetime risk of cervical cancer in older, unvaccinated, HPV-negative women: a modelling study.
Malagón T; Kulasingam S; Mayrand MH; Ogilvie G; Smith L; Bouchard C; Gotlieb W; Franco EL
Lancet Oncol; 2018 Dec; 19(12):1569-1578. PubMed ID: 30392810
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of cervical cancer screening with primary HPV testing for unvaccinated women in Sweden.
Fogelberg S; Clements MS; Pedersen K; Sy S; Sparén P; Kim JJ; Burger EA
PLoS One; 2020; 15(9):e0239611. PubMed ID: 32997696
[TBL] [Abstract][Full Text] [Related]
13. The potential harms of primary human papillomavirus screening in over-screened women: a microsimulation study.
Naber SK; de Kok IM; Matthijsse SM; van Ballegooijen M
Cancer Causes Control; 2016 Apr; 27(4):569-81. PubMed ID: 26970740
[TBL] [Abstract][Full Text] [Related]
14. Economic evaluation of strategies for managing women with equivocal cytological results in Brazil.
Vanni T; Legood R; Franco EL; Villa LL; Luz PM; Schwartsmann G
Int J Cancer; 2011 Aug; 129(3):671-9. PubMed ID: 20886598
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of increasing cervical cancer screening coverage in the Middle East: An example from Lebanon.
Sharma M; Seoud M; Kim JJ
Vaccine; 2017 Jan; 35(4):564-569. PubMed ID: 28017434
[TBL] [Abstract][Full Text] [Related]
16. Cervical cancer screening among HIV-infected women: an economic evaluation in a middle-income country.
Vanni T; Luz PM; Grinsztejn B; Veloso VG; Foss A; Mesa-Frias M; Legood R
Int J Cancer; 2012 Jul; 131(2):E96-104. PubMed ID: 21964797
[TBL] [Abstract][Full Text] [Related]
17. Cervical Cancer Screening in Partly HPV Vaccinated Cohorts - A Cost-Effectiveness Analysis.
Naber SK; Matthijsse SM; Rozemeijer K; Penning C; de Kok IM; van Ballegooijen M
PLoS One; 2016; 11(1):e0145548. PubMed ID: 26824771
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of HPV vaccination alongside cervical cancer screening programme in Slovenia.
Obradovic M; Mrhar A; Kos M
Eur J Public Health; 2010 Aug; 20(4):415-21. PubMed ID: 20624834
[TBL] [Abstract][Full Text] [Related]
19. The combined impact of implementing HPV immunisation and primary HPV screening in New Zealand: Transitional and long-term benefits, costs and resource utilisation implications.
Hall MT; Smith MA; Lew JB; O'Hallahan J; Fentiman G; Neal H; Sage M; Canfell K
Gynecol Oncol; 2019 Mar; 152(3):472-479. PubMed ID: 30876491
[TBL] [Abstract][Full Text] [Related]
20. To expand coverage, or increase frequency: Quantifying the tradeoffs between equity and efficiency facing cervical cancer screening programs in low-resource settings.
Campos NG; Tsu V; Jeronimo J; Mvundura M; Lee K; Kim JJ
Int J Cancer; 2017 Mar; 140(6):1293-1305. PubMed ID: 27925175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
